tis, 5 for psoriasis and 3 for Crohn's disease. Available information for each condition is presented hereafter. In rheumatoid arthritis, absenteeism ranged from 25 to 56 days per year and presenteeism was estimated to 55 days. The mean cost of absenteeism in this condition ranged from €709 to €10,166. In ankylosing spondylitis, annual absenteeism ranged from 6 to 65 days, which represented €726 to €2,532 per patient. Presenteeism was estimated to 14 days loss with an associated annual cost of €1,027. In psoriasis, annual absenteeism ranged from 3 to 14 days and presenteeism from 16 to 35 days. The costs of work productivity loss (absenteeism ϩ presenteeism) in psoriasis ranged from €1,675 to €6,300. In Crohn's disease, annual absenteeism was of 120 days per patient in median, which represented a cost of €4,745. No data on presenteeism was found. CONCLUSIONS: Chronic immune-mediated inflammatory diseases have a high impact on work productivity loss due to both number of days at work lost and decreased performance with substantial costs. 
OBJECTIVES:
To assess the improvement in work productivity associated with adalimumab therapy in chronic immune-mediated inflammatory diseases. METHODS: A systematic and computerized search was performed in the literature published in English from 2000 to 2011 in Pubmed. The search terms were: 'crohn disease', 'spondylitis, ankylosing', 'psoriasis', 'rheumatoid arthritis', 'work productivity', 'productivity', 'absenteeism', 'sick leave', 'employment status' and 'adalimumab'. Questionnaires used to measure the work productivity were identified. Results were annualized and costs converted in Euros and actualized to 2010 using exchange rates and price indexes provided by the Organisation for Economic Cooperation and Development. RESULTS: Nine clinical trials and one meta-analysis were analyzed: 5 in rheumatoid arthritis, 1 in ankylosing spondylitis, 3 in psoriasis and 1 in Crohn's disease. Work Productivity and Activity Impairment (WPAI) questionnaire was used in 62% of studies. In rheumatoid arthritis, adalimumab was associated with a 8-to-21-working day per year decrease in absenteeism and an 8-to-10-day decrease in presenteeism. In ankylosing spondylitis, adalimumab was associated with a decrease of 8 working days per year in absenteeism and a 50 day decrease in presenteeism. In psoriasis, adalimumab was associated with a decrease of 27 days in presenteeism but no significant improvement of absenteeism was observed in this condition. In patients with moderate to severe Crohn's disease, treatment with adalimumab was associated with a 18 working day per year decrease in absenteeism and a 47-day decrease in presenteeism. Costs saving related to increased global work productivity (absenteeism and presenteeism) were estimated to €1,720 per patient per year in rheumatoid arthritis and €7,625 in Crohn's disease. CONCLUSIONS: Adalimumab provided clinically significant improvements in work productivity that could be associated with savings of to € 7,625 in improved work productivity in Crohn's disease. 
PSY17 ESTIMATING THE DIRECT COSTS OF PATIENTS TREATED WITH ELTROMBOPAG IN THE FRENCH SETTING

OBJECTIVES:
Immune thrombocytopenia (ITP) is an immunologic blood disorder characterised by low platelet counts and bleeding. The management of ITP aimed at minimising bleeding events. Eltrombopag is an oral thrombopoietin receptor agonist indicated as second line treatment of chronic ITP in adults. This economic study estimated the direct costs of ITP management with eltrombopag in the French setting. METHODS: A phase III clinical trial (RAISE) compared the response to once daily eltrombopag versus placebo in adult patients with chronic ITP during a 6-month period. Use of medical resources was assessed from the RAISE data regarding eltrombopag dosage, treatment duration, bleeding-related events (BREs grade 2ϩ), rescue therapy (IVIG, oral steroids), concomitant medications and hospitalisations. The economic analysis was restricted to direct costs (2011 values) measured in the perspective of the French Sickness Fund (full coverage for ITP). RESULTS: For 6 months of treatment, total cost per patient receiving eltrombopag (mean dose: 55.2mg) was estimated at 15,318 € with 88.9 % of the costs induced by the main drug treatment. Monitoring costs related to eltrombopag (blood tests and visits) were estimated at 403 € (2.6%). At least, concomitant drugs, BREs and rescue therapy were respectively accounting for 623 € (4.1%), 730 € (4.8%) and 344 € (2.2%). These results seem consistent with other French economic estimations concerning patients treated with IVIG (13,291 €/6 months) or patient treated with romiplostim (3g/Kg, 17,486 €/6 months). CONCLUSIONS: With the data from the RAISE clinical trial, the direct cost for a patient treated with eltrombopag during a 6 months period was estimated at 15,318 €. Estimation of direct costs may be envisaged in an exploratory manner when Phase III clinical trials are close to real practice management and has to be confirmed by collected resource utilization in observational studies. OBJECTIVES: Day-to-day clinical practice outcomes and related costs are important not only to confirm clinical trial results but also to inform more efficiently clinical decision making. The objective of this retrospective study was to characterize the main treatment outcomes and associated costs of a MDS and AML patient's population in a hematology center in Portugal. METHODS: Adult patients (nϭ27) with MDS or AML at diagnosis and eligible for treatment with azacitidine at any stage of their disease were eligible. Retrospective data was obtained from hospital clinical records. Treatment outcomes included time-to-leukemia (TTL), leukemia-free survival (LFS) and overall survival (OS). Survival analysis was performed with the standard non-parametric Kaplan-Meier method. Costs were estimated by multiplying resource utilization frequencies by their unit prices. RESULTS: Mean follow-up was 15 months (min-max: 2.1-31.2). Mean (SD) age at diagnosis was 67 (11) From the health care system perspective, costs considered were those associated with test strips, physician visits, pharmacist time and patient training. From the societal perspective, the additional costs associated with the acquisition of the monitoring machine, and time dedicated to monitoring were considered. RESULTS: Annual costs per patient of 372.53 CAD$ and 397.27 CAD$ were associated with standard monitoring and PSM respectively under the health care system perspective. Annual costs per patient were estimated at 1,116.08 CAD$ for standard monitoring while annual PSM costs were estimated at 533.19 CAD$ under the societal perspective. Both OAT methods were shown to be clinically equivalent, however a significant improvement of QoL was found in PSM. CONCLUSIONS: From the health care system perspective, PSM is slightly more expensive than standard monitoring of OAT (ϩ24,74 CAD$), but from the societal perspective PSM is associated with significant savings compared to standard monitoring of OAT . Also, PSM is associated with improves patient's QoL while assuring the same monitoring quality as standard monitoring of OAT. Federico II University of Naples, Naples, Italy OBJECTIVES: To assess the cost-effectiveness of prophylaxis vs on-demand therapy with Anti Inhibitor Complex Concentrate (AICC). METHODS: Hemophilia A patients Ͼ2 years with inhibitors and using bypassing therapy to treat bleeding were recruited in a prospective, randomized, crossover study comparing 6 months of AICC prophylaxis therapy with 6 months of on-demand therapy. The prophylactic and on demand periods were separated by a 3-month washout. Cost evaluation was based on direct (clotting factors, hospitalization, outpatient care, physicians' visit and other pharmacological therapy) and indirect (days of school/work missed because of bleeding) costs, adopting the perspective of the third party payer. Costs are expressed in US$ of 2011. We calculated the incremental cost per bleeding avoided and the cost-effectiveness acceptability-curve. RESULTS: Twenty-six patients were enrolled. The per-patient six-months cost during prophylaxis period was 496,393 US$ compared with 211,330 US$ on on-demand. The incremental cost-effectiveness ratio in the prophylaxis vs on demand period was 34,852 per bleeding event avoided. The acceptability curve showed there would be a 93% likelihood that prophylaxis therapy would be considered cost-effective at willingness-to-pay threshold of US$ 50,000 per bleeding event avoided. In Subjects with a Ն50% reduction in bleeding events, the incremental cost-effectiveness ratio in the prophylaxis vs on demand period was US$ 25,877 per bleeding event avoided. In A511 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
PSY18 CLINICAL OUTCOMES, RESOURCE UTILIZATION AND TREATMENT COST OF MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOIDE LEUKEMIA IN A REAL WORLD SETTING: SINGLE-CENTER EXPERIENCE
PSY20 COST-EFFECTIVENESS OF PROPHYLAXIS WITH AN ANTI-INHIBITOR COMPLEX CONCENTRATE IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS: RESULTS FROM PRO-FEIBA STUDY
